Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: BIIB022|DRUG: Sorafenib
To evaluate the safety and tolerability of BIIB022 given once every 3 weeks in combination with sorafenib in subjects with advanced HCC., 6 months
To evaluate the PK profile of BIIB022 and sorafenib in this study population, 6 months|To assess the anti-tumor response in this study population, 6 months
This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.